Deferred tax asset (liability) (Details) - USD ($) |
3 Months Ended | 6 Months Ended | 12 Months Ended | |
|---|---|---|---|---|
Dec. 31, 2025 |
Dec. 31, 2024 |
Sep. 30, 2024 |
Sep. 30, 2025 |
|
| Income Tax Disclosure [Abstract] | ||||
| Research & Development expenses | $ 315,075 | $ 3,650 | $ 156,462 | |
| Stock based compensation | 45,000 | 0 | 0 | 30,000 |
| Net operating loss | $ (6,567,681) | $ (203,724) | $ (332,119) | $ (6,741,189) |
| X | ||||||||||
- Definition Amount of expense for employee benefit and equity-based compensation. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|